Skip to main content
SpringerLink
Log in

Antiepileptogenic Agents

How Close Are We?

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Epilepsy is a common neurological condition, affecting about 4% of individuals over their lifetime. Epilepsy can be idiopathic, secondary to an underlying genetic abnormality or unknown causes, or acquired. Known potential causes account for about one third of epilepsy. Control of epilepsy has primarily focused on suppressing seizure activity after epilepsy has developed. An intriguing possibility is to control acquired epilepsy by preventing epileptogenesis, the process by which the brain becomes epileptic. Many laboratory models simulate human epilepsy as well as provide a system for studying epileptogenesis. The kindling model involves repeated application of subconvulsive electrical stimulation to the brain, leading to spontaneous seizures. Other models include the cortical or systemic injection of various chemicals. These models suggest that many anti-epileptic drugs, from phenobarbital and valproate (valproic acid) to levetiracetam and tiagabine, have antiepileptogenic potential. Some promising other possibilities include N-methyl-D-aspartate (NMDA) or alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) antagonists as well as the neurotrophins and their receptors.

Phenobarbital, phenytoin, valproate, carbamazepine and, to a very limited extent, diazepam have been evaluated in clinical trials to test whether they actually prevent epileptogenesis in humans. Results have been very disappointing. Meta-analyses of 12 different drug-condition combinations show none with significantly lower unprovoked seizure rates among those receiving the active drug. In 4 of the 12, the observed rate was actually slightly higher among treated individuals. None of the newer drugs have been evaluated in antiepileptogenesis trials. Until some drugs demonstrate a clear antiepileptogenic effect in clinical trials, the best course to reduce the incidence of epilepsy is primary prevention of the risk-increasing events — for example, wearing helmets, using seat belts, or decreasing the risk of stroke by reducing smoking.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1

Similar content being viewed by others

References

  1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34(3): 453–68

    Article  PubMed  CAS  Google Scholar 

  2. Annegers JF, Shirts SB, Hauser WA, et al. Risk of recurrence after an initial unprovoked seizure. Epilepsia 1986; 27(1): 43–50

    Article  PubMed  CAS  Google Scholar 

  3. Schuh LA, Henry TR, Fromes G, et al. Influence of head trauma on outcome following anterior temporal lobectomy. Arch Neurol 1998; 55(10): 1325–8

    Article  PubMed  CAS  Google Scholar 

  4. Schwartzkroin PA: Epileptogenesis. In: Aminoff M, Daroff R, editors. Encyclopedia of neurological sciences. San Diego: Academic Press. In press

  5. Hoff H, Hoff H. Fortschritte in der Behandlung der Epilepsie. Mschr Psychiat Neurol 1947; 114: 105–18

    Article  Google Scholar 

  6. Rapport RL, Penry JK. A survey of attitudes toward the pharmacological prophylaxis of posttraumatic epilepsy. J Neurosurg 1973; 38(2): 159–66

    Article  PubMed  Google Scholar 

  7. Loscher W. Animal models of intractable epilepsy. Prog Neurobiol 1997; 53(2): 239–58

    Article  PubMed  CAS  Google Scholar 

  8. Fariello RG. Critical review of the animal models of generalized epilepsies. Ital J Neurol Sci 1995; 16(1–2): 69–72

    Article  PubMed  CAS  Google Scholar 

  9. March PA. Seizures: classification, etiologies, and pathophysiology. Clin Tech Small Anim Pract 1998; 13(3): 119–31

    Article  PubMed  CAS  Google Scholar 

  10. De Deyn PP, D’Hooge R. Animal models of focal epilepsy. Acta Neurol Belg 1999; 99(4): 222–5

    PubMed  Google Scholar 

  11. Yang L, Benardo LS. Valproate prevents epileptiform activity after trauma in an in vitro model in neocortical slices. Epilepsia 2000; 41(12): 1507–13

    Article  PubMed  CAS  Google Scholar 

  12. Sagratella S. Characterization of the in vitro antiepileptic activity of new and old anticonvulsant drugs. Gen Pharmacol 1998; 30(2): 153–60

    Article  PubMed  CAS  Google Scholar 

  13. McNamara JO. Analyses of the molecular basis of kindling development. Psychiatry Clin Neurosci 1995; 49(3): S175–178

    Article  PubMed  CAS  Google Scholar 

  14. Silver JM, Shin C, McNamara JO. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilespy. Ann Neurol 1991; 29(4): 356–63

    Article  PubMed  CAS  Google Scholar 

  15. Goddard GV, Mclntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969; 25(3): 295–330

    Article  PubMed  CAS  Google Scholar 

  16. Wada J, Sato M, Wake A. Prophylactic effects of phenytoin, phenobarbital and carbamazepine examined in kindling cat preparations. Arch Neurol 1976; 33: 426–34

    Article  PubMed  CAS  Google Scholar 

  17. Shirasaka Y, Wasterlain CG. Chronic epileptogenicity following focal status epilepticus. Brain Res 1994; 655(1–2): 33–44

    Article  PubMed  CAS  Google Scholar 

  18. Halonen T, Nissinen J, Jansen JA, et al. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur J Pharmacol 1996; 299(1–3): 69–81

    Article  PubMed  CAS  Google Scholar 

  19. Cronin J, Dudek FE. Chronic seizures and collateral sprouting of dentate mossy fibers after kainic acid treatment in rats. Brain Res 1988; 474(1): 181–4

    Article  PubMed  CAS  Google Scholar 

  20. Krall RL, Penry JK, Kupferberg HJ, et al. Antiepileptic drug development: I. History and a program for progress. Epilepsia 1978; 19(4): 393–408

    Article  PubMed  CAS  Google Scholar 

  21. Krall RL, Penry JK, White BG, et al. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978; 19(4): 409–28

    Article  PubMed  CAS  Google Scholar 

  22. Cavalheiro EA, Santos NF, Priel MR. The pilocarpine model of epilepsy in mice. Epilepsia 1996; 37(10): 1015–9

    Article  PubMed  CAS  Google Scholar 

  23. Priel MR, dos Santos NF, Cavalheiro EA. Developmental aspects of the pilocarpine model of epilepsy. Epilepsy Res 1996; 26(1): 115–21

    Article  PubMed  CAS  Google Scholar 

  24. Jefferys JG, Borck C, Mellanby J. Chronic focal epilepsy induced by intracerebral tetanus toxin. Ital J Neurol Sci 1995; 16(1–2): 27–32

    Article  PubMed  CAS  Google Scholar 

  25. Doi T, Ueda Y, Tokumaru J, et al. Sequential changes in glutamate transporter mRNA levels during Fe(3+)-induced epileptogenesis. Brain Res Mol Brain Res 2000; 75(1): 105–12

    Article  PubMed  CAS  Google Scholar 

  26. Meldrum BS. Identification and preclinical testing of novel antiepileptic compounds. Epilepsia 1997; 38 Suppl. 9: S7–15

    Article  PubMed  CAS  Google Scholar 

  27. Morimoto K, Sato H, Sato K, et al. BW1003C87, phenytoin and carbamazepine elevate seizure threshold in the rat amygdala-kindling model of epilepsy. Eur J Pharmacol 1997; 339(1): 11–5

    Article  PubMed  Google Scholar 

  28. Marescaux C, Micheletti G, Vergnes M, et al. A model of chronic spontaneous petit mal-like seizures in the rat: comparison with pentylenetetrazol-induced seizures. Epilepsia 1984; 25(3): 326–31

    Article  PubMed  CAS  Google Scholar 

  29. Schwark WS, Haluska M. Prophylaxis of amygdala kindling-induced epileptogenesis: comparison of a GABA uptake inhibitor and diazepam. Epilepsy Res 1987; 1(1): 63–9

    Article  PubMed  CAS  Google Scholar 

  30. Morita Y, Shinkuma D, Shibagaki N, et al. Effect of benzodiazepine derivatives on amygdaloid-kindled convulsion. Folia Psychiatr Neurol Jpn 1982; 36(4): 391–9

    PubMed  CAS  Google Scholar 

  31. Wise RA, Chinerman J. Effects of diazepam and phenobarbital on electrically-induced amygdaloid seizures and seizure development. Exp Neurol 1974; 45(2): 355–63

    Article  PubMed  CAS  Google Scholar 

  32. Wada JA. Pharmacological prophylaxis in the kindling model of epilepsy. Arch Neurol 1977; 34(7): 389–95

    Article  PubMed  CAS  Google Scholar 

  33. Becker A, Grecksch G, Brosz M. Antiepileptic drugs—their effects on kindled seizures and kindling-induced learning impairments. Pharmacol Biochem Behav 1995; 52(3): 453–9

    Article  PubMed  CAS  Google Scholar 

  34. Frey HH, Bartels I. Felbamate and meprobamate: a comparison of their anticonvulsant properties. Epilepsy Res 1997; 27(3): 151–64

    Article  PubMed  CAS  Google Scholar 

  35. Walton NY, Jaing Q, Hyun B, et al. Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. Epilepsy Res 1996; 24(1): 19–28

    Article  PubMed  CAS  Google Scholar 

  36. Postma TE, Krupp XL, Li RM, et al. Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy. Epilepsia 2000; 41(12): 1514–21

    Article  PubMed  CAS  Google Scholar 

  37. Loscher W. New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 1998; 342(1): 1–13

    Article  PubMed  CAS  Google Scholar 

  38. Matagne A, Klitgaard H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res 1998; 31(1): 59–71

    Article  PubMed  CAS  Google Scholar 

  39. Lathers CM, Schraeder PL, Turner N. The effect of phenobarbital on autonomic function and epileptogenic activity induced by the hippocampal injection of penicillin in cats. J Clin Pharmacol 1993; 33(9): 837–44

    PubMed  CAS  Google Scholar 

  40. Edmonds HL, Stark LG, Hollinger MA. The effects of diphenylhydantoin, phenobarbital, and diazepam on the penicillininduced epileptogenic focus in the rat. Exp Neurol 1974; 45(2): 377–86

    Article  PubMed  CAS  Google Scholar 

  41. Mares P, Pohl M. Effect of phenobarbital on cortical epileptogenic foci in the rat. Physiol Bohemoslov 1981; 30(1): 63–71

    PubMed  CAS  Google Scholar 

  42. Lockard JS, DuCharme LL, Congdon WC, et al. Prophylaxis with diphenylhydantoin and phenobarbital in alumina-gel monkey model. II. Four-month follow-up period: seizure, EEG, blood, and behavioral data. Epilepsia 1976; 17: 49–57

    Article  PubMed  CAS  Google Scholar 

  43. Ehle AL. Effects of phenytoin on amygdaloid kindled seizures in the rat. Electroencephalogr Clin Neurophysiol 1980; 48(1): 102–5

    Article  PubMed  CAS  Google Scholar 

  44. Rundfeldt C, Honack D, Loscher W. Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats. Neuropharmacology 1990; 29(9): 845–51

    Article  PubMed  CAS  Google Scholar 

  45. Turner IM, Newman SM, Louis S, et al. Pharmacological prophylaxis against the development of kindled amygdaloid seizures. Ann Neurol 1977; 2(3): 221–4

    Article  PubMed  CAS  Google Scholar 

  46. Applegate CD, Smoriski GM, Ozduman K. Effects of valproate, phenytoin, and MK-801 in a novel model of epileptogenesis. Epilepsia 1997; 38(6): 631–6

    Article  PubMed  CAS  Google Scholar 

  47. Sherwin I. Suppressant effects of diphenylhydantoin on the cortical epileptogenic focus. Neurology 1973; 23(3): 274–81

    Article  PubMed  CAS  Google Scholar 

  48. Mares P, Maresova D, Smejkalova V. Effect of diphenyl-hydantion on cortical epileptogenic foci in the rat. Physiol Bohemoslov 1983; 32(1): 19–29

    PubMed  CAS  Google Scholar 

  49. Lockard JS, Congdon WC, DuCharme LL, et al. Prophylaxis with diphenylhydantoin and phenobarbital and alumina-gel monkey model. I. Twelve months of treatment: seizure, EEG, blood, and behavioral data. Epilepsia 1976; 17(1): 37–47

    Article  PubMed  CAS  Google Scholar 

  50. Dalby NO, Nielsen EB. Tiagabine exerts an anti-epileptogenic effect in amygdala kindling epileptogenesis in the rat. Neurosci Lett 1997; 229(2): 135–7

    Article  PubMed  CAS  Google Scholar 

  51. Amano K, Hamada K, Yagi K, et al. Antiepileptic effects of topiramate on amygdaloid kindling in rats. Epilepsy Res 1998; 31(2): 123–8

    Article  PubMed  CAS  Google Scholar 

  52. Shin C, Rigsbee LC, McNamara JO. Anti-seizure and anti-epileptogenic effect of gamma-vinyl gamma-aminobutyric acid in amygdaloid kindling. Brain Res 1986; 398(2): 370–4

    Article  PubMed  CAS  Google Scholar 

  53. Halonen T, Nissinen J, Pitkanen A. Chronic elevation of brain GAB A levels beginning two days after status epilepticus does not prevent epileptogenesis in rats. Neuropharmacology 2001; 40(4): 536–50

    Article  PubMed  CAS  Google Scholar 

  54. Lowenstein DH. Recent advances related to basic mechanisms of epileptogenesis. Epilepsy Res Suppl 1996; 11: 45–60

    PubMed  CAS  Google Scholar 

  55. McNamara JO, Russell RD, Rigsbee L, et al. Anticonvulsant and antiepileptogenic actions of MK-801 in the kindling and electroshock models. Neuropharmacology 1988; 27(6): 563–8

    Article  PubMed  CAS  Google Scholar 

  56. Kodama M, Yamada N, Sato K, et al. Effects of YM90K, a selective AMPA receptor antagonist, on amygdala-kindling and long-term hippocampal potentiation in the rat. Eur J Pharmacol 1999; 374(1): 11–9

    Article  PubMed  CAS  Google Scholar 

  57. Kokaia M, Ernfors P, Kokaia Z, et al. Suppressed epileptogenesis in BDNF mutant mice. Exp Neurol 1995; 133(2): 215–24

    Article  PubMed  CAS  Google Scholar 

  58. Van der Zee CE, Rashid K, Le K, et al. Intraventricular administration of antibodies to nerve growth factor retards kindling and blocks mossy fiber sprouting in adult rats. J Neurosci 1995; 15 (7 Pt 2): 5316–23

    PubMed  Google Scholar 

  59. Binder DK, Routbort MJ, Ryan TE, et al. Selective inhibition of kindling development by intraventricular administration of TrkB receptor body. J Neurosci 1999; 19(4): 1424–36

    PubMed  CAS  Google Scholar 

  60. Temkin NR, Haglund MM, Winn HR. Post-traumatic seizures. In: Youmans JR, editor. Neurological surgery. 4th ed. Vol. 3. Philadelphia: W.B. Saunders Company, 1996: 1834–9

    Google Scholar 

  61. Manaka S. Cooperative prospective study on posttraumatic epilepsy: risk factors and the effect of prophylactic anticonvulsant. J Psychiatry Neurol 1992; 46: 311

    CAS  Google Scholar 

  62. Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg 1999; 91(4): 593–600

    Article  PubMed  CAS  Google Scholar 

  63. Birkmayer W. Die Behandlung der tramatischen Epilepsie. Wein klin Wschr 1951; 63: 603–9

    Google Scholar 

  64. Young B, Rapp RP, Norton JA, et al. Failure of prophylactically administered phenytoin to prevent early post-traumatic seizures. J Neurosurg 1983; 58: 231–5

    Article  PubMed  CAS  Google Scholar 

  65. Young B, Rapp RP, Norton JA, et al. Failure of prophylactically administered phenytoin to prevent late post-traumatic seizures. J Neurosurg 1983; 58: 236–41

    Article  PubMed  CAS  Google Scholar 

  66. McQueen JK, Blackwood D, Harris P, et al. Low risk of late post-traumatic seizures following severe head injury: implications for clinical trials of prophylaxis. J Neurol Neurosurg Psychiatry 1983; 46(10): 899–904

    Article  PubMed  CAS  Google Scholar 

  67. Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, double-blind study of phenytoin for the prevention of posttraumatic seizures. N Engl J Med 1990; 323(8): 497–502

    Article  PubMed  CAS  Google Scholar 

  68. Pechadre JC, Lauxerois M, Colnet G, et al. Prevention de l’epilepsie post-traumatique tardive par phenytoine dans les traumatismes craniens graves: suivi durant 2 ans. Presse Medicale 1991; 20(18): 841–5

    CAS  Google Scholar 

  69. Popek K, Musil F. Clinical attempt to prevent post-traumatic epilepsy following severe brain injuries in adults. Cas Lek Cesk 1969; 108(5): 133–47

    PubMed  CAS  Google Scholar 

  70. Penry JK, White BG, Brackett CE. A controlled prospective study of the pharmacologic prophylaxis of post-traumatic epilepsy. Neurology 1979; 29: 600–1

    Article  Google Scholar 

  71. Glötzner FL, Haubitz I, Miltner F, et al. Anfallsprophylaxe mit Carbamazepin nach schweren Schadelhirnverletzungen. Neurochirurgia (Stutt) 1983; 26: 66–79

    Google Scholar 

  72. Shaw MD, Foy PM. Epilepsy after craniotomy and the place of prophylactic anticonvulsant drugs: discussion paper. J R Soc Med 1991; 84(4): 221–3

    PubMed  CAS  Google Scholar 

  73. North JB, Penhall RK, Hanieh A, et al. Phenytoin and postoperative epilepsy: A double-blind study. JNeurosurg 1983; 58: 672–7

    Article  CAS  Google Scholar 

  74. Burn J, Dennis M, Bamford J, et al. Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. BMJ 1997; 315(7122): 1582–7

    Article  PubMed  CAS  Google Scholar 

  75. Hesdorffer DC, Logroscino G, Cascino G, et al. Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. Ann Neurol 1998; 44(6): 908–12

    Article  PubMed  CAS  Google Scholar 

  76. Annegers JF, Hauser WA, Beghi E, et al. The risk of unprovoked seizures after encephalitis and meningitis. Neurology 1988; 38(9): 1407–10

    Article  PubMed  CAS  Google Scholar 

  77. Nelson KB, Ellenberg JH. Predictors of epilepsy in children who have experienced febrile seizures. N Engl J Med 1976; 295(19): 1029–33

    Article  PubMed  CAS  Google Scholar 

  78. Knudsen FU, Paerregaard A, Andersen R, et al. Long term outcome of prophylaxis for febrile convulsions. Arch Dis Child 1996; 74(1): 13–8

    Article  PubMed  CAS  Google Scholar 

  79. Sulzbacher S, Farwell JR, Temkin N, et al. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr (Phila) 1999; 38(7): 387–94

    Article  CAS  Google Scholar 

  80. Wolf SM, Forsythe A. Epilepsy and mental retardation following febrile seizures in childhood. Acta Paediatr Scand 1989; 78: 291–5

    Article  PubMed  CAS  Google Scholar 

  81. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001; 42(4): 515–24

    Article  PubMed  CAS  Google Scholar 

  82. The Cochrane Collaboration. RevMan 4.1 user guide. In: Oxford: Update Software, 2000

    Google Scholar 

  83. Franceschetti S, Binelli S, Casazza M, et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir 1990; 103(1–2): 47–51

    Article  CAS  Google Scholar 

  84. Wolf SM, Carr A, Davis DC, et al. The value of phenobarbital in the child who has had a single febrile seizure: a controlled prospective study. Pediatrics 1977; 59(3): 378–85

    PubMed  CAS  Google Scholar 

  85. Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures - effects on intelligence and on seizure recurrence [published erratum appears in N Engl J Med 1992 Jan 9; 326 (2): 144]. N Engl J Med 1990; 322(6): 364–9

    Article  PubMed  CAS  Google Scholar 

  86. Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996; 46(4): 985–91

    Article  PubMed  CAS  Google Scholar 

  87. Holland JP, Stapleton SR, Moore AJ, et al. A randomized double blind study of sodium valproate for the prevention of seizures in neurosurgical patients. J Neurol Neurosurg Psychiatry 1995; 58: 116

    Article  Google Scholar 

  88. Rosman NP, Colton T, Labazzo J, et al. A controlled trial of diazepam administered during febrile illnesses to prevent recurrence of febrile seizures. N Engl J Med 1993; 329(2): 79–84

    Article  PubMed  CAS  Google Scholar 

  89. Lee ST, Lui TN, Chang CN, et al. Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol 1989; 31(5): 361–4

    Article  PubMed  CAS  Google Scholar 

  90. Foy P, Chadwick D, Rajgopalan N, et al. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy? J Neurol Neurosurg Psychiatry 1992; 55: 753–7

    Article  PubMed  CAS  Google Scholar 

  91. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54(10): 1886–93

    Article  PubMed  CAS  Google Scholar 

  92. Beenen LF, Lindeboom J, Kasteleijn-Nolst Trenite DG, et al. Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects. J Neurol Neurosurg Psychiatry 1999; 67(4): 474–80

    Article  PubMed  CAS  Google Scholar 

  93. Dikmen S, Temkin N, Miller B, et al. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991; 265: 1271–7

    Article  PubMed  CAS  Google Scholar 

  94. Smith Jr KR, Goulding PM, Wilderman D, et al. Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study. Arch Neurol 1994; 51(7): 653–60

    Article  PubMed  Google Scholar 

  95. Dikmen SS, Machamer JE, Winn HR, et al. Neuropsychological effects of valproate in traumatic brain injury: a randomized trial. Neurology 2000; 54(4): 895–902

    Article  PubMed  CAS  Google Scholar 

  96. Thompson DC, Rivera FP, Thompson R. Helmets for preventing head and facial injuries in bicyclists (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2000

    Google Scholar 

  97. Tsai MC, Hemenway D. Effect of the mandatory helmet law in Taiwan. Inj Prev 1999; 5(4): 290–1

    Article  PubMed  CAS  Google Scholar 

  98. Lestina DC, Williams AF, Lund AK, et al. Motor vehicle crash injury patterns and the Virginia seat belt law. Jama 1991; 265(11): 1409–13

    Article  PubMed  CAS  Google Scholar 

  99. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association [see comments]. JAMA 1999; 281(12): 1112–20

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grant NIN-NINDS R01NS19643.

Author information

Authors and Affiliations

  1. Department of Neurological Surgery, University of Washington, Box 359924, 325 Ninth Avenue, Seattle, Washington, 98104-2499, USA

    Nancy R. Temkin, Abel D. Jarell & Gail D. Anderson

  2. Department of Biostatistics, University of Washington, Seattle, Washington, USA

    Nancy R. Temkin

  3. Department of Pharmacy, University of Washington, Seattle, Washington, USA

    Gail D. Anderson

Authors
  1. Nancy R. Temkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abel D. Jarell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gail D. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nancy R. Temkin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Temkin, N.R., Jarell, A.D. & Anderson, G.D. Antiepileptogenic Agents. Drugs 61, 1045–1055 (2001). https://doi.org/10.2165/00003495-200161080-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161080-00002

Keywords

Search

Navigation